Admixture Mapping of an Allele Affecting Interleukin 6 Soluble Receptor and Interleukin 6 Levels  by Reich, David et al.
716 The American Journal of Human Genetics Volume 80 April 2007 www.ajhg.org
ARTICLE
Admixture Mapping of an Allele Affecting Interleukin 6 Soluble
Receptor and Interleukin 6 Levels
David Reich, Nick Patterson, Vijaya Ramesh, Philip L. De Jager, Gavin J. McDonald, Arti Tandon,
Edwin Choy, Donglei Hu, Bani Tamraz, Ludmila Pawlikowska, Christina Wassel-Fyr,
Scott Huntsman, Alicja Waliszewska, Elizabeth Rossin, Rongling Li, Melissa Garcia,
Alexander Reiner, Robert Ferrell, Steve Cummings, Pui-Yan Kwok, Tamara Harris,
Joseph M. Zmuda, and Elad Ziv, for the Health, Aging and Body Composition (Health ABC) Study
Circulating levels of inflammatory markers can predict cardiovascular disease risk. To identify genes influencing the levels
of these markers, we genotyped 1,343 single-nucleotide polymorphisms (SNPs) in 1,184 African Americans from the
Health, Aging and Body Composition (Health ABC) Study. Using admixture mapping, we found a significant association
of interleukin 6 soluble receptor (IL-6 SR) with European ancestry on chromosome 1 (LOD 4.59), in a region that includes
the gene for this receptor (IL-6R). Genotyping 19 SNPs showed that the effect is largely explained by an allele at 4%
frequency in West Africans and at 35% frequency in European Americans, first described as associated with IL-6 SR in a
Japanese cohort. We replicate this association ( ) and also demonstrate a new association with circulating512P K 1.0# 10
levels of a different molecule, IL-6 ( ). After replication in 1,674 European Americans from Health ABC, the55P ! 3.4# 10
combined result is even more significant: for IL-6 SR, and for IL-6. These results also serve512 59P K 1.0# 10 P ! 2.0# 10
as an important proof of principle, showing that admixture mapping can not only coarsely localize but can also fine
map a phenotypically important variant.
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Circulating markers of inflammation, particularly C-re-
active protein (CRP) and interleukin 6 (IL-6), are associ-
ated with risk of atherosclerosis, myocardial infarction,
stroke, and the progression of autoimmune disease, al-
though the reasons for these associations remain unclear.1–
7 Whereas environmental exposures have a major influ-
ence, genetic factors also play a role; for example, CRP,
IL-6, and tumor necrosis factor a (TNF-a) have been shown
to be heritable in family studies8–10 and twin studies,11–13
motivating searches to find the relevant genetic factors.
In the United States, the levels of inflammatory markers
are systematically different in European Americans com-
pared with African Americans, with CRP levels higher in
African Americans14 and with IL-6 and IL-6 soluble recep-
tor (IL-6 SR) levels higher in European Americans.15 These
observations prompted our search for genetic loci that
affect these markers and contribute to the epidemiolog-
ical differences across populations.
The idea of admixture mapping16–26 is to study a pop-
ulation of recently mixed ancestry, such as African Amer-
icans, searching for genomic regions where individuals
with a specific phenotype have an unusually high pro-
portion of ancestry from one ancestral population. Be-
cause of the recent mixture of Europeans and Africans,
segments of contiguous European or African ancestry in
African Americans have not had much time (only ∼6 gen-
erations, on average) to break up by recombination.22–25
Tracking these segments requires genotyping SNPs every
couple of million base pairs along the genome, instead of
the 100–1,000 times higher density required by whole-
genome linkage disequilibrium scans.27
Several recent studies have reported significant associ-
ations with the use of admixture mapping. Zhu et al.28
reported two loci for hypertension in African Americans
on chromosomes 6 and 21. We reported a locus on chro-
mosome 1 where increased European ancestry is associ-
ated with a risk of multiple sclerosis29 and a locus on chro-
mosome 8 where increased African ancestry is associated
with a risk of prostate cancer.30 Unfortunately, the regions
of association identified by admixture mapping are broad
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Table 1. Association Tests for Eight Markers of Inflammation
Marker Median (Range)
No. of
Samplesa
P for
Correlation
to Ancestryb
Admixture Scansc
No. of Cases/
Controls
No. of
SNPs
Genome
Score
Best LOD
Score
IL-6 2.0 pg/ml (.3–14.2) 1,099 .23 230/226 1,343 .71 1.42
CRP 2.1 mg/liter (.3–63.9) 1,156 .0084 238/230 1,342 .57 1.55
PAI1 21 ng/ml (2–280) 1,143 .17 234/228 1,342 .29 1.71
TNFa 3.0 pg/ml (.6–14.2) 1,082 .23 217/217 1,342 .62 1.23
TNF-a SR1 3,296 pg/ml (1,725–6,059) 569 .50 108/113 1,331 .43 1.16
TNF-a SR2 1,394 pg/ml (513–4,428) 553 .51 115/118 1,326 .38 1.52
IL-6 SR 30,743 pg/ml (9,010–65,506) 572 .00012 114/117 1,336 2.03 4.59
IL-2 SR 1,087 pg/ml (454–4,431) 571 .020 117/111 1,330 .40 1.47
a For each phenotype, we analyzed only samples for which information was available for the phenotype of interest and all seven covariates—
age, sex, site of collection, smoking status, diabetes status, BMI, and abdominal visceral fat mass.
b IL-6 SR is significantly positively associated with European ancestry, and CRP is negatively associated.
c Admixture scans compared highest 20% with lowest 20% for each phenotype.
(similar to peaks from linkage studies), and no study has
yet moved from an initial peak of admixture association
to localizing the exact genetic variant(s) involved. We re-
port an admixture mapping study that first coarsely lo-
calizes and then precisely identifies a genetic variant that
explains the admixture peak.
Material and Methods
Human Subjects
All biological materials came from Health, Aging and Body Com-
position (Health ABC) Study participants, a cohort of 3,075 men
and women aged 70–79 years and enrolled between April 1997
and June 1998. All participants were Medicare beneficiaries living
near Pittsburgh or Memphis. All participants reported no diffi-
culty performing basic physical activities. Of the 3,075 partici-
pants enrolled, 1,281 reported their ethnicity as black, and we
successfully genotyped 1,184 samples.
Clinical and Phenotypic Information
The eight inflammatory markers we studied are IL-6 (np 1,123
measured samples), CRP ( ), plasminogen-activating in-np 1,181
hibitor (PAI1 [ ]), TNF-a ( ), TNF-a SR1 (np 1,168 np 1,102 np
), TNF-a SR2 ( ), IL-6 SR ( ), and IL-2 SR (564 np 576 np 583 np
). The soluble receptors were assayed in only about half the579
samples. To measure the level of these markers, venipuncture was
performed for each of the participants after an overnight fast of
at least 8 h, and serum samples were then frozen at 70C. CRP
was measured by colorimetric competitive ELISA (Macy Labora-
tory) with an intra-assay coefficient of variation (CV) of 5.14%.
IL-6 and TNF-a were measured by solid-phase ELISA (R&D Sys-
tems) with CVs of 13.1%–18.1% for IL-6 and 14.8%–14.9% for
TNF-a. PAI1 was measured by a two-site ELISA (Collen Laboratory)
with a CV of 3.47%. TNF-a SR1, TNF-a SR2, IL-6 SR, and IL-2 SR
were all measured by ultrasensitive ELISA (R&D Systems) and had
CVs of 5.0%–6.7%, 7.8–8.4%, 3.5%–5.2%, and 4.3%–4.9%,
respectively.
Seven additional pieces of information were used as covariates
because of their known correlation with inflammatory marker
levels31: sex, clinic site, age, self-reported status as a smoker, di-
abetes status (self-reported or based on use of antidiabetes med-
ications or on having a fasting blood glucose level of 1126), BMI,
and abdominal visceral fat mass (measured at the L4–L5 vertebrae
by CT scans).
Genotyping
DNA from the African American samples was whole-genome am-
plified32 before genotyping at the Broad Institute. We used the
Illumina BeadLab platform33 to assay 1,536 SNPs previously iden-
tified as highly informative about African versus European an-
cestry.16,29,30 After performing quality checks identical to those
described by Reich et al.,29 we were left with 1,343 SNPs that
genotyped well in 1,184 samples. These SNPs had previously been
genotyped in an average of 104 West African and 241 European-
derived samples,30 and we used these data to improve allele-fre-
quency estimates in the parental populations of African Am-
ericans.22,23 For follow-up analysis around the IL-6R gene (MIM
147880), we used the Sequenom MassArray platform34 to geno-
type an additional 20 SNPs in all the African Americans, of which
18 passed quality checks.29,30 For replication genotyping of
rs8192284 in European Americans, we used template-directed
dye-terminator incorporation with fluorescence polarization de-
tection (Acycloprime II kit [PerkinElmer])35 on genomic DNA at
the University of California–San Francisco.
Reduced SNP Panels
The ANCESTRYMAP software identifies SNPs that appear to be in
linkage disequilibrium with one another in the ancestral West
African and European American populations or that are not ap-
propriately intermediate in frequency in African Americans be-
tween the ancestral West African and European American pop-
ulations.23 These SNPs were removed before analysis. Since the
samples included in each admixture scan were slightly different
(depending on the phenotype), the algorithm removed slightly
different sets of SNPs for each run, leaving 1,326–1,343 SNPs for
analysis (table 1). We present results for the 1,299 SNPs common
to all runs in tab-delimited ASCII file data set 1 (online only).
Adjusting for Covariates
The main admixture scans used the raw values of the phenotypes
without adjustment for covariates. For tests of association be-
tween overall ancestry and the rs8192284 genotype, we adjusted
for the seven covariates of age, sex, clinic site (Memphis or Pitts-
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Table 2. Testing SNPs for Their Ability to Explain the Admixture Association
SNP
Position on
Chromosome
1a
SNP-
Specific
LOD
Score
ANOVA
Percentage of
Locus-Specific
IL-6 SR Association
Explained by
SNP Genotype Alone
Association at SNP
Admixture
Association
Not Explained
by SNP
x2 P x2 P
rs11582424 151177058 .9 3 .27 38 7.7#1010 7
rs11265608 151177213 .7 .2 .90 39 5.0#1010 0
rs952146 151182001 .9 .8 .67 38 7.4#1010 2
rs4845615 151188350 .6 .8 .66 41 1.7#1010 1
rs1552481 151189426 .5 1 .61 46 1.4#1011 3
rs4845617 151190971 .9 4 .13 38 6.9#1010 10
rs1386821 151195122 .3 6 .047 37 9.2#1010 15
rs4845618 151213088 8.6 79 K1.0#1012 34 6.1#109 72
rs7549250 151217409 5.6 59 K1.0#1012 39 4.5#1010 63
rs7518199 151220492 11.0 114 K1.0#1012 21 4.0#106 86
rs4845623 151228850 10.9 50 1.1#1011 58 K1.0#1012 49
rs4845625 151235140 8.8 48 3.9#1011 51 1.1#1012 51
rs8192284 151240043 13.6 195 K1.0#1012 2 .13 99
rs11265618 151243165 .6 13 .0015 36 2.1#109 27
rs4329505 151245493 .8 2 .29 37 1.3#109 6
rs7526293 151257282 1.8 34 3.8#108 25 4.6#107 59
rs12568083 151269022 1.0 66 K1.0#1012 5 .025 93
rs4845632 151272005 .0 24 5.2#106 23 1.3#106 52
rs12740969 151300133 3.6 63 K1.0#1012 3 .071 95
NOTE.—We used a look-up table to convert x2 statistics to P values: 2 df for the test of genotype association
and 1 df for the test for admixture association beyond genotype. We do not present exact P values when P K
, since it is not clear that the statistics follow an exact x2 distribution at such extremely significant121.0# 10
values. There is no evidence of an ancestry association beyond rs8192284. The SNP genotype explains 99% of
the association evidence at the locus, and the P value for additional admixture association not explained by
the SNP is .13. All tests reported in this table were uncorrected for covariates.
a Position according to build 35 of the human genome reference sequence.
burgh), smoking status, diabetes status, BMI, and abdominal vis-
ceral adiposity.
Normalizing Transformations
For the analysis of variance (ANOVA), we needed to obtain nor-
mally distributed values for all eight quantitative traits. As re-
ported in tables 1 and 2, we performed a “probit” transforma-
tion,36 by rank-ordering all individuals according to their values
for each trait and by assigning Z scores corresponding to percen-
tiles in a normal distribution. For example, an individual with
CRP in the 97.7th percentile in the population would be assigned
. The probit transformation, although it ensures normality,Zp 2
is based solely on the ordering of samples, and so it loses quan-
titative information. To quantitatively assess the effect of the
rs8192884 genotype on IL-6 and IL-6 SR levels, we replaced the
probit transformation with a natural-logarithm transformation.
Admixture Mapping
We used the ANCESTRYMAP software23 to screen the genome in
the African Americans from Health ABC, searching for association
to genomic segments with an increased proportion of European
or African ancestry. Since ANCESTRYMAP is optimized for the
analysis of dichotomous traits,23 we ran the analysis comparing
the 20% of individuals with the highest values as cases and the
20% with the lowest values as controls. To test for association,
we prespecified a set of risk models. We tested 18 models and
averaged the factors in favor of each model, to assess overall evi-
dence of association.23 The first six models used 2.5-fold, 2-fold,
1.5-fold, 0.67-fold, 0.5-fold, and 0.4-fold increased risk due to
European ancestry for cases, with the inverse risk in controls. The
next six models used the same set of increased risk for cases, but
with a control risk of 1. The last six models specified that cases
had risk 1, whereas the controls had risks of 0.4, 0.5, 0.67, 1.5,
2.0, and 2.5. All Markov chain–Monte Carlo runs used 100 burn-
in and 200 follow-on iterations, as recommended on the basis of
simulation studies.23
Assessing Statistical Significance for the Admixture Scan
The ANCESTRYMAP software produces a score of association at
each position in the genome: the LOD10 at that point in the
genome indicates that there is an association with disease, versus
a model with no disease. The whole-genome score is the average
of the local odds ratios for genomewide association; we interpret
a score 12 as genomewide significant23 and observe a score of 2.03
for IL-6 SR. As a secondary analysis, the software also searches for
a difference in ancestry proportion between cases and controls23
(data set 1 [online only]).
Credible Interval for the Position of the Disease-Causing
Variant(s)
To identify a 99% Bayesian credible interval for the position of
the disease-causing variant,23,29,30 we used a uniform prior distri-
bution for its position across the genetic distance span of chro-
mosome 1. We multiplied the factor in favor of association at
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each point by this prior distribution. The credible interval is de-
fined as the central region with 99% of the area.
Fine-Mapping Strategy around the IL-6R Gene
To follow up the evidence of association to IL-6 SR levels, we
picked haplotype-tagging SNPs across the IL-6R gene and the 10
kb of flanking sequence in both directions. The SNPs were chosen
using data from the first phase of the International Haplotype
Map (HapMap) database (release 16c)37 and the Tagger program.38
To form a comprehensive tag set that was appropriate to both
ancestral populations of African Americans, we picked SNPs to
tag all haplotypes in West Africans (YRI from HapMap). We then
forced these SNPs into the tag set and picked additional SNPs to
tag variation in European Americans (CEU from HapMap). We
stopped choosing SNPs when all HapMap SNPs with minor-allele
frequency 10% in the region were correlated to one of the tag
SNPs at . Nineteen tag SNPs were thereby selected, to2r  0.7
which we added rs8192284, an amino acid–changing SNP that
had been identified by Galicia et al.39 as being associated with IL-
6 SR in Japan. We also studied another SNP in the vicinity that
had been typed in the admixture scan.
Detecting an Allele Contributing to the Admixture Mapping
Signal
To test whether a SNP allele contributes more to the phenotype
than can be expected from the ancestry association alone, we
used a new feature of the ANCESTRYMAP software (appendix A).
We calculated an allele-specific LOD score corresponding to the
likelihood of a disease model containing a specific contribution
of the allele versus no contribution of the allele and found there
is only an admixture association. We observe a highly significant
score of 13.6 at rs8192284.
How Much of the Admixture Signal Is Explained
by an Allele?
To test whether the rs8192284 polymorphism explains the entire
admixture signal, we performed nested ANOVA. First, we assessed
how much of the variance in probit-transformed IL-6 SR levels
can be explained by genotype status (e.g., zero, one, or two copies
of the C allele at rs8192284), providing a P value for association
to each SNP. Next, we assessed how much the variance increases
when we add the local estimate of ancestry from ANCESTRYMAP
into the ANOVA. The increase in x2 produces a P value for there
being residual admixture association not explained by the SNP.
To assess how much of the evidence of association is attributable
to the SNP, we divided the amount of variance explained in the
first ANOVA (SNP alone) by the amount in the second (SNP plus
local ancestry).
Testing for rs8192284 Associations with Several
Inflammatory Markers
To test the association of rs8192284 with each of the inflam-
matory markers in African Americans as well as in European
Americans, we controlled for the seven covariates in ANOVA. For
the African Americans, we also added the overall proportion of
European ancestry for each individual. To test for rs8192284 as-
sociation, we used all the samples from the Health ABC Study,
not only the top and bottom quintiles.
Quantifying the Contribution of the rs8192284 Genotype
to Levels of IL-6 SR and IL-6
IL-6 SR and IL-6 levels were natural-log transformed. We used
ANOVA to determine the effect of the rs8192284 genotype on
these levels, before and after controlling for covariates. The values
that emerged were exponentiated, to evaluate the effect of the
different genotypes on absolute levels of IL-6 and IL-6 SR (table
3).
Testing for a Nonmultiplicative Effect
To assess whether the effect of rs8192284 on a phenotype (IL-6
or IL-6 SR) was appropriately fit by a multiplicative model, we
calculated a likelihood ratio. We first calculated the x2 fit for the
data under a one-parameter model in which the log-transformed
values of the phenotype increased additively with increasing
numbers of copies of the C allele. We then calculated the x2 fit
under a two-parameter model in which a separate increased risk
was allowed for one or two copies of the C allele. These analyses
controlled for the seven main covariates, and the analyses in
African Americans additionally controlled for the overall per-
centage of European ancestry.
Testing Whether the IL-6 SR Antibody Binds to the Variant
Encoded by rs8192284
To determine whether the anti-human IL-6R monoclonal anti-
body used to assay IL-6 SR levels displays a preferential binding
affinity to a specific epitope (particularly the D358A substitution
encoded by rs8192284), we synthesized custom peptides corre-
sponding to the entire amino acid sequence (468 residues) and
spotted them onto a cellulose membrane. Synthesized spots in-
cluded 230 overlapping 10-mer peptides with an offset of 2 aa,
115 overlapping 11-mer peptides with an offset of 4 aa, and 39
peptides that specifically focused on tiling the region of the IL-
6R protein flanking amino acid 358. We spotted numerous pep-
tides that captured both A allele and D allele variants. Employing
a modified protocol from Sigma-Genosys and standard immu-
noblotting methods,40 we incubated the membrane with the anti–
IL-6 SR monoclonal antibody at a concentration of 10 mg/ml in
buffer containing 2% milk/TBS-T for 3 h at room temperature
(TBS-T is Tris-buffered saline with 0.05% Tween 20, composed of
25 mM Tris, 0.14 M NaCl, and 0.05% Tween 20), followed by
incubation with a horseradish peroxidase–conjugatedanti-mouse
secondary antibody at a dilution of 1:10,000 in buffer containing
2% milk/TBS-T for 2 h at room temperature. Positive spots were
visualized using Amersham chemiluminescent reagents and were
imaged by autoradiographic exposure at 1 h and 16 h.
Lymphoblastoid Cell-Line Experiment
Lymphoblastoid cell lines (LCL) from the HapMap Project (269
of 270) were interrogated for cell-surface expression of IL-6R. The
LCLs were grown for 7 d in batches of 96 LCLs in RPMI 1640
media with 2 mmol L-glutamine, 1x penicillin and streptomycin,
and 10% Fetalplex serum. From each LCL, ∼25,000 cells were
incubated with R-Phycoerythrin–conjugated mouse anti-human
IL-6R (catalog number 551850 [BD Pharmingen]) at 4C for 30
min. Cells were washed once with PBS and 1% fetal bovine serum
and were fixed with 1% paraformaldehyde. Data on cell-surface
expression of IL-6R in each cell line were acquired using a fluo-
rescence-activated cell sorter (BD Biosciences FACSCalibur sys-
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Table 3. Quantitative Effect of rs8192284 on Levels of IL-6 SR and IL-6
Marker, Genotype
at rs8192284,
and Population
No. of
Samples
Marker Level
(pg/ml  SD)
No Correction for Covariates Correction for Covariatesa
Multiplicative
Effect on
Level
P vs. AA
Genotype
Multiplicative
Effect on
Level
P vs. AA
Genotype
IL-6 SR:
AA:
African American 419 29,665  5,245 … … … …
European American 278 31,476  5,188 … … … …
AC:
African American 157 38,894  8,735 1.29 K1.0#1012 1.28 K1.0#1012
European American 400 40,790  6,323 1.28 K1.0#1012 1.29 K1.0#1012
CC:
African American 16 46,543  7,286 1.53 K1.0#1012 1.65 K1.0#1012
European American 127 49,371  8,129 1.57 K1.0#1012 1.55 K1.0#1012
IL-6:
AA:
African American 833 2.55  2.14 … … … …
European American 586 2.16  1.87 … … … …
AC:
African American 290 2.71  1.84 1.13 .006 1.15 .006
European American 802 2.25  1.74 1.09 .014 1.06 .095
CC:
African American 32 3.39  2.29 1.43 .002 1.43 .004
European American 246 2.53  1.83 1.24 .000004 1.22 .0001
a We corrected for the seven covariates; for African Americans, we also corrected for overall percentage of European ancestry.
tem). To quantify IL-6R expression for each LCL, we used flow
cytometry, requiring at least 500 cells per LCL for it to be reported
in our analysis. Fluorescence intensity was measured for both the
anti–IL-6R antibody and a control isotype antibody for each cell
and was assessed in 1,024 equally sized bins.41,42 The normalized
intensity in each bin was defined as the number of anti–IL-6R–
labeled cells minus the number of isotype control–labeled cells.
To convert into a single measurement of fluorescence intensity,
we averaged across all cells (by summing across the bins) and
reported the natural logarithm. To test for statistical significance
of fluorescence intensity between genotype classes, we used a t
test.
Results
We first tested whether the levels of eight inflammatory
markers—IL-6, CRP, PAI1, TNF-a, TNF-a SR1, TNF-a SR2,
IL-6 SR, and IL-2 SR—were correlated to the proportion of
European ancestry in the 1,184 African American partic-
ipants in the Health ABC Study. After correcting for age,
sex, clinic site, smoking status, diabetes status, BMI, and
abdominal visceral fat mass, which are known to be cor-
related to inflammatory marker levels,31 we found evi-
dence of a significant correlation of high IL-6 SR levels
with increased European ancestry ( ) and highPp .00012
CRP levels with increased African ancestry ( ).Pp .0084
The correlation to ancestry suggests that admixture map-
ping may find genes underlying these phenotypes.
We performed eight admixture scans,23 comparing the
20% of the samples with the highest values of each phe-
notype with the 20% of samples with the lowest values.
Only one scan produced significant evidence of associa-
tion with IL-6 SR levels. The peak LOD score for this phe-
notype was 4.59 on chromosome 1, and the genomewide
score reaches the threshold of 2.03 for significance23,26 (ta-
ble 1 and fig. 1). Formally, this does not meet our criterion
for statistical significance if we correct for the eight hy-
potheses we tested. However, the peak appeared to be wor-
thy of further study, especially since the IL-6R gene lo-
calizes to the peak.
When we repeated the analysis on all 583 samples with
measured IL-6 SR levels (not just the samples with the
highest and lowest levels), we noticed that the evidence
of association to IL-6 SR levels was contributed almost
entirely by the individuals with the highest 10%–30% of
IL-6 SR levels. To show this, we used the fact that the
ANCESTRYMAP software generates a LOD score at each
position in the genome not only for all individuals treated
together but also for each individual separately. When we
rank-ordered all the 583 individuals with a measurement
of IL-6 SR, we were able to test which samples were con-
tributing most to association. The score increases to a max-
imum for the top 10% of IL-6 SR values and drops after
the top 30% (fig. 2). This suggests that the association is
explained by a major-effect allele at higher frequency in
European Americans than in West Africans and carried by
10%–30% of African Americans.
To localize the putative allele affecting IL-6 SR levels,
we constructed a 99% credible interval for its position.
Both admixture mapping and linkage mapping in fam-
ilies generate coarse initial localizations of a disease-caus-
ing locus, in contrast with whole-genome linkage dis-
equilibrium mapping, in which the initial localization is
usually within tens of kilobases.26 In this study, the initial
localization spans 119.0–151.7 Mb in the human genome
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Figure 1. Admixture scan for loci affecting levels of IL-6 SR. The analysis was performed by comparing the 20% of African Americans
with the highest levels ( ) with the 20% with the lowest levels ( ) of IL-6 SR. A significant signal was contributed bynp 114 np 117
a peak on chromosome 1 (LOD 4.59). Factor-averaging the LOD scores across the genome (to correct for multiple-hypothesis testing)
produced a significant genomewide score of 2.03. We also observed a secondary peak with a LOD score of 3.45 on chromosome 9, but
this does not reach our published threshold for suggestiveness.26
reference sequence (human genome reference sequence
build 35) and contains dozens of genes. However, we no-
ticed that the peak contains the IL-6R gene (at position
151.19–151.25 Mb), an excellent candidate for contain-
ing variants contributing to IL-6 SR levels. A recent candi-
date-gene study by Galicia and colleagues39 already identi-
fied genetic variants in the IL-6R gene that affected levels
of IL-6 SR in Japanese ( for the most-associatedP ! .0001
rs8192284 SNP). For follow-up fine mapping, we geno-
typed rs8192284, as well as 20 other variants surrounding
the IL-6R gene that tagged all the common variation of
at least 10% minor-allele frequency in both West Africans
and European Americans from HapMap.37 A total of 19
SNPs produced usable data.
We employed ANCESTRYMAP23 to test for association
to IL-6 SR levels above and beyond the admixture asso-
ciation. This identified five SNPs with extremely signifi-
cant associations to IL-6R levels (single-SNP LOD scores
all 18) (table 2). All were within an ∼40-kb segment of
very strong linkage disequilibrium in both West Africans
and European Americans.37 The SNP with the strongest
association is rs8192284 (LOD 13.6), the same polymor-
phism that was associated to IL-6 SR levels in Japanese.39
As Galicia et al.39 pointed out, rs8192284 is an excellent
candidate as a SNP that modulates IL-6 SR levels. Since it
occurs at the proteolytic cleavage site of IL-6R,39 variabil-
ity could affect levels of the circulating soluble receptor.
Moreover, the variant is highly differentiated in frequency
across populations (35% in European Americans and 4%
in West Africans in HapMap), which is consistent with it
producing a differential risk across populations and ex-
plains the admixture signal.
Our statistical analysis suggests that rs8192284 is suffi-
cient to explain the admixture peak. First, when we tested
whether there is any evidence of an admixture association
above and beyond the contribution of the genotype at
rs8192284, we found no significant evidence ( ). OfPp .13
the 19 SNPs we tested, this is the only one consistent with
explaining the entire admixture signal (table 2). Second,
in ANOVA, the genotype at rs8192284 explains 99% of
the total association we have detected to IL-6 SR levels,
which is again consistent with ancestry not capturing any
additional signal (table 2). Finally, the effect of rs8192284
on IL-6 SR can be seen visually: when we control for ge-
notype—that is, subtract the average IL-6 SR level for each
of the three genotype classes—the distribution of absolute
IL-6 SR levels becomes approximately Gaussian (data not
shown), and its variance is reduced by 33%.
We were concerned that, although the association we
detected is real, it might reflect an artifact of the mea-
surement technique rather than genuinely high circulat-
ing levels of IL-6 SR. In particular, the epitope of the mono-
clonal antibody used to measure IL-6 SR levels might
contain the rs1892284 polymorphism itself (D358A,
changing an aspartic acid to an alanine). A polymorphism
within the antibody’s epitope could produce an associa-
tion of the measurement of IL-6 SR to rs8192284 but
would not be biologically interesting (this effect could also
be produced by a coding polymorphism in strong linkage
disequilibrium with rs8192284, but there is no such poly-
morphism present in the human HapMap). To rule out
the possibility of a binding artifact at rs8192294, we spot-
ted peptides tiling the entire IL-6R protein onto a cellulose
array and performed immunodetection with the same
monoclonal antibody used to assay IL-6 SR in the Health
ABC Study. There was no evidence of binding to peptides
encoding either D358 or A358 (fig. 3). IL-6 SR is known
to arise by two different mechanisms, either by proteolytic
cleavage of IL-6R at the cell surface or by a secreted splice
isoform of IL-6R.43 Although the peptide sequences of
these two different IL-6 SR forms are slightly different,
neither contains residue 358, which adds to the weight of
evidence that the effect on levels that we observed is not
explained by a polymorphism within the epitope of the
anti–IL-6 SR antibody.
Galicia et al., in their original study of a Japanese cohort,
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Figure 2. The 10%–30% of individuals with the highest IL-6 SR levels contributing most of the association. We rank-ordered 584
African Americans by their measured levels of IL-6 SR, from highest to lowest, not correcting for covariates. We ran ANCESTRYMAP,
treating all samples as cases, and calculated the log factor of disease association for each sample under three models: (1) 2.5-fold
increased risk for European ancestry associated with case status, the model that provided the strongest contribution to disease risk;
(2) 1.5-fold increased risk for European ancestry; and (3) 1.25-fold increased risk for African ancestry. For model 1, the LOD score
increased dramatically for the top 10% (peak LOD 6.57) of levels until the 30th percentile and then decreased, indicating that the
signal was likely to be contributed only by the individuals with the highest 10%–30% of IL-6 SR levels.
Figure 3. Immunodetection showing no evidence that the IL-6
SR antibody preferentially binds to D358A. We spotted 10-mer, 11-
mer, and 12-mer peptides from the IL-6R protein onto a cellulose
array with 384 features and immunodetected with the IL-6 SR
monoclonal antibody employed in the ELISA assay to study the
subjects in the Health ABC Study. Three potential peptide spots
from the 10-mers were detected, including an intense positive
signal (spot #110 at amino acids 219–228) and two other positive
signals (spot #68 at amino acids 135–144 and spot #144 at amino
acids 287–296). No intense spots overlapped amino acid 358,
which we spotted in both polymorphic forms and was included in
numerous peptides. Results are from a 1-h exposure (similar results
were obtained from an overnight exposure [not shown]).
noticed that the DNA polymorphism rs8192284 (protein
polymorphism D358A) occurred at the site where IL-6R is
cleaved to form IL-6 SR.39 This observation led them to
hypothesize that the way the SNP modulates IL-6 SR levels
is by affecting the efficiency of cleavage of the circulating
receptor from the membrane-bound form. To test this, we
quantified the amount of surface IL-6R on the LCLs from
the HapMap Project, which should not be substantially
affected if the cleavage hypothesis is explaining the high
levels in serum. A survey of cell lines from several different
ethnic groups shows no evidence of an association of sur-
face IL-6R with the rs8192284 genotype in HapMap cell
lines (fig. 4). This supports the hypothesis of Galicia et al.
that the mechanism of action of rs8192284 is to affect
cleavage efficiency of IL-6 SR from the cell membrane.39
Motivated by the quantitatively profound effect of
rs8192284 on IL-6 SR levels and the observation that some
of the other markers of inflammation are in the same bi-
ological pathway, we next tested for an association of the
genotype to levels of the other seven inflammatory mark-
ers. We found that rs8192284 is associated not only with
IL-6 SR levels ( ) but also—a novel finding—12PK 1.0# 10
with IL-6 levels ( ).5P ! 3.4# 10
To replicate both the IL-6 SR and IL-6 associations, we
studied 1,674 European Americans for whom we had com-
plete information for the seven covariates and for whom
we successfully obtained an rs8192284 genotype. (These
samples were a subset of the 1,794 European Americans
in the Health ABC Study.) The association with IL-6 SR
was extremely significant at . We also rep-12PK 1.0# 10
licated the association with IL-6 ( ). When6P ! 8.9# 10
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Figure 4. rs8192284 does not appear to affect levels of IL-6R protein on the cell surface. We measured expression of surface IL-6R
protein on LCLs used in the HapMap Project and found no significant effect of the rs8192284 genotype. We plotted the distribution
of IL-6R expression for unrelated European Americans from Utah (CEU), East Asians from Beijing (CHB) and Tokyo (JPT), and West
Africans from Ibadan, Nigeria (YRI). The AA homozygotes are represented by red triangles, AC heterozygotes by green diamonds, and
CC homozygotes by blue dots. The mean value of each genotype class is represented by a horizontal black line. P values for differences
between each genotype class (t test) are reported. The low frequency of the C allele in the YRI samples (4%) limits the power of the
analysis in this group (the frequencies are 35% in CEU and 43% in CHB and JPT).
the African American and European American samples
were combined and when self-declared ancestry and per-
centage of European ancestry were controlled for in the
analysis, both associations were extremely significant
( for IL-6 SR and for IL-6).12 9PK 1.0# 10 P ! 2.0# 10
We next assessed how the AC and CC genotypes at
rs81922284 raise inflammatory marker levels, relative to
AA (table 3). The rs8192284 genotype explains 33% of the
variance in absolute IL-6 SR levels in African Americans
and 49% in European Americans. IL-6 SR levels are in-
creased, on average, 1.29-fold per copy of the allele in
African Americans and 1.26-fold per copy in European
Americans, after correction for covariates. There is no evi-
dence of a nonmultiplicative effect of the allele in African
Americans ( ) and only marginal evidence in Eu-Pp .88
ropean Americans ( ). The effect on IL-6 levels isPp .05
quantitatively less; the rs8192284 genotype explains 0.8%
of the variance in absolute IL-6 levels in African Ameri-
cans and 0.4% in European Americans. After correction
for covariates, IL-6 is increased, on average, 1.17-fold per
copy of the allele in African Americans and 1.10-fold per
copy of the allele in European Americans. We do not de-
tect a nonmultiplicative effect in either African Americans
( ) or European Americans ( ) for the asso-Pp .60 Pp .26
ciation to IL-6 levels.
Discussion
We have used admixture mapping to search for regions
of the genome associated with eight acute-phase inflam-
matory markers and soluble receptors. We identified a
32.7-Mb region on chromosome 1 (including the centro-
mere) at which high levels of European ancestry in African
Americans are significantly associated with high levels of
IL-6 SR.28,29,30 It is also important to highlight the negative
results: seven of the eight phenotypes failed to show as-
sociations. One possible explanation is low sample size.
The scans in this study included only a couple hundred
samples with each extreme phenotype, but our power cal-
culations suggest that 11,000 samples should be studied
for admixture mapping to have high statistical power
compared with alternative methods such as linkage map-
ping.23,26 It is important to recognize, however, that ad-
mixture scans can have negative results, even with large
samples sizes. For example, we have performed scans for
BMI and type 2 diabetes, which, despite containing12,000
samples, fail to detect association (D. Reich and N. Pat-
terson, unpublished data).
The admixture mapping study identified a missense SNP
in the IL-6R gene, rs8192284, which was first associated
with IL-6 SR levels in 114 Japanese individuals.39 We show
that alleles at this SNP fully account for the admixture
peak on chromosome 1. Our analysis powerfully replicates
the result found by Galicia et al.39 in two additional ethnic
groups and also provides quantitative information about
the importance of the effect. An association with IL-6 SR
is interesting not only because of the association of in-
flammatory markers to atherosclerosis but also because IL-
6 SR has been associated in vivo to the pathophysiology
of autoimmune diseases, including rheumatoid arthritis
(MIM 180300), ulcerative colitis, and Crohn disease (MIM
191390).43
A novel result in this study is that rs8192284 is also
associated with IL-6 levels in both African Americans and
European Americans. There is a 1.06- to 1.15-fold in-
creased level of IL-6 for one copy of the allele and a 1.22-
to 1.43-fold increase for two copies, accounting for 0.8%
of the variance in IL-6 measurements in African Americans
and for 0.4% in European Americans. Although the caus-
ative SNP in the IL-6R locus is associated with higher IL-
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6 levels, admixture mapping did not detect a signal for
IL-6 at this locus. The lack of a signal for IL-6 as the phe-
notype at this locus is not surprising given our limited
sample size and the fact that the association between
rs8192284 and IL-6 SR (33%–49% of variance explained)
is so much stronger than the association with IL-6 (!1%
of variance explained). Our previously published power
calculations23 suggest that several thousand individuals
with extreme values of IL-6 would be necessary to directly
detect an association with IL-6 levels at the IL-6R locus in
African Americans. High IL-6 levels are biologically im-
portant, since they are correlated with risk of coronary
heart disease and mobility disability.44 In one study of
postmenopausal women,6 individuals in the highest quar-
tile of IL-6 levels have more than double the rate of cor-
onary artery disease of those in the lowest quartile. We do
not know whether rs8192284 is associated with coronary
heart disease risk, but this study identifies it as a candidate
risk variant.
Finally, this study is methodologically significant be-
cause it provides the first evidence that admixture map-
ping can be used to localize and precisely map phenotyp-
ically important variants. Past studies have used admix-
ture mapping to provide rough localization.29,30,33 How-
ever, no study has followed an initial localization with a
successful positional cloning effort. Similar to previous ad-
mixture mapping studies,28–30 this study identified a wide
region around the peak containing many genes. The pres-
ence of IL-6R in this region was fortuitous in allowing us
to narrow the search to a small region. However, the
strength of the signal we found at multiple tag SNPs
around IL-6 SR indicates that mapping would also have
been successful (although it would have required more
genotyping) if we had instead taken the approach of hap-
lotype tagging across the entire admixture peak. Thus, this
study demonstrates that an admixture scan followed by
haplotype tagging across a peak can identify causal
variants.
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Appendix A
We extended our ANCESTRYMAP software23 to allow us
to detect not only a locus with increased proportion of
European or African ancestry compared with the ge-
nomewide average (an admixture peak) but also a variant
that contributes more to association than can be explained
by the admixture signal alone. As in the original work of
Patterson et al.,23 the fine-mapping test for statistical as-
sociation uses Bayesian statistics.
To review the approach we used to search for an ad-
mixture peak in ANCESTRYMAP, we model the risk of
disease for an individual due to ancestry at a locus as
. Here, a is the number of European ancestry chro-aw(a)p r
mosomes (0, 1, or 2) that individual has, and r is the mul-
tiplicative risk per European chromosome. To score for
association, we calculate , which can be summed overL (i)1
all individuals to obtain overall evidence of admixture as-
sociation at the locus,
2 2
L (i)p log g (a,i)w(a) log v(a,i)w(a) . 1 t
ap0 ap0
Here, is the estimated probability that an individualg (a,i)t
has a European chromosomes at the position of interest
t, and is the genomewide proportion of Europeanv(a,i)
ancestry. Both of these are calculated by the ANCESTRY-
MAP software.23
To extend the model to calculate a fine-mapping score
at a specific marker, we score for risk as a joint function
of ancestry a and genotype g: w(a,g). The relevant score is
now
2 2
L (i)p log g (a,i)w(a,g) log v(a,i)w(a) . 2 t
ap0 ap0
A contrast between the main admixture score andL (i)1
the fine-mapping score is that, for the admixtureL (i)2
mapping score, we are comparing the hypothesis that Eu-
ropean ancestry at the locus modulates risk of disease with
the hypothesis that the locus has nothing to do with dis-
ease. For the fine-mapping score, we are comparing the
hypothesis that the allele or one in strong linkage dis-
equilibrium with it modulates a phenotype with the hy-
pothesis that the locus is indeed connected with disease
but only by an admixture signal. Thus, the fine-mapping
score gives evidence of association above and beyondL (i)2
the admixture signal .L (i)1
All that remains is to specify the joint risk function
. We model it as . In this formula-w(a,g) w(a,g)p X(a)Y(g)
tion, ancestry and genotype contribute multiplicatively
and independently to risk. We specify a regularly spaced
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mesh on genotype logY(g), to test different models of dis-
ease risk. Given a particular Y(g), we then set X(a) such
that it reduces to w(a) in the case in which genotype makes
no additional contribution. Thus, we set X(a) so that
. Our final score is an average of theE[w(a,g)Fa]p w(a)
Bayes factors obtained at each mesh point. This yields a
Bayes factor for the compound hypothesis that the ge-
notype is contributing to the score.
Web Resources
The URLs for data presented herein are as follows:
ANCESTRYMAP software, http://genepath.med.harvard.edu/
˜reich/Software.htm
International HapMap Project, http://www.hapmap.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for IL-6R, rheumatoid arthritis, and
Crohn disease)
UCSC Genome Browser, http://genome.ucsc.edu/ (for human ge-
nome reference sequence build 35)
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